2VJ.MU Stock Analysis
2V
Uncovered
Ascletis Pharma Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 315 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).